Bausch Health (BHC)
(Delayed Data from NYSE)
$6.50 USD
-0.27 (-3.99%)
Updated May 20, 2024 04:00 PM ET
After-Market: $6.50 0.00 (0.00%) 4:50 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
Brokerage Reports
Bausch Health Cos Inc. [BHC]
Reports for Purchase
Showing records 81 - 100 ( 148 total )
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Opthalmics-Focused Spinout Planned; 2Q20 Financials; Lowering PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Legacy Investigation Resolved; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Pandemic Impact Abating; Universe Re-Rating; Raising PT to $64
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Bausch Opportunistically Grabs More XIPERE Rights; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Rifaximin Novel Formulation Positive Phase 2 Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Recent Attrition Appears Overdone; Reiterate Buy; Modulating Target to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
XIPERE Positive Pivotal Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Further Debt Management; Securities Litigation Resolved; Pipeline Advances; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Guidance Raised; Multiple Recent Advances; Raising Target to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R